RGENRepligen Corporation
Is the business good?
The checks split: 7 of 9 health tests passed and earnings fully cash-backed (2.6×), but margins compressing.
High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.
Operating profit is fully backed by cash.
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
A balanced mix of margins, efficiency, and leverage. ROE 2% = margin × turnover × leverage.
Unless marked, from derived.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is RGEN?
Repligen Corporation earns 2.8% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 6.2 points below what the capital costs: growth destroys value
- Operating margin
- 8.2%
Operating margin · Medical Instruments & Supplies median 6.6% · 12 months to Q2 2026
- Cash conversion
- 2.62×
Cash conversion · operating cash flow covers the operating profit after tax
- Share count, year on year
- +0.23%
Share count, year on year · flat: no meaningful dilution
| Year | Operating margin |
|---|---|
| FY2020 | 19% |
| FY2021 | 25% |
| FY2022 | 28% |
| FY2023 | 7.5% |
| FY2024 | −5.5% |
| FY2025 | 7.5% |
Details›
- Gross margin12 months to Q2 2026
- 54%
- Operating margin12 months to Q2 2026
- 8.2%
- Net margin12 months to Q2 2026
- 5.3%
- Free cash flow margin
- 14%
- R&D as % of revenue
- 7.1%
- Revenue, trailing twelve months
- $785M
- Free cash flow, trailing twelve months
- $112M
- Net income, trailing twelve months
- $42M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 2.8%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Medical Instruments & Supplies
Ranks #11 of 21 by RyuScore